Trusted Press Release Distribution   Plans | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Pareesh Phulkar
pareesh@coherentmarketinsights.com
www.coherentmarketinsights.com/

Bookmark and Share
Plant-Based Vaccines Market 2018 : Sales Revenue Analysis and Major Manufacturers Performance 2026
Key players in the global plant-based vaccines market are focused on in-organic growth strategies such as strategic collaborations and acquisition to harness R&D capabilities in development of new plant-based vaccines.

BriefingWire.com, 9/13/2019 - Plants are a cost-effective, safe, and efficacious platform for large-scale production of vaccine in emerging economies and have the potential via oral administration to elicit a mucosal immune response. Key players in the market are focused on Research & Development (R&D) activities for development of plant-based vaccines for the treatment of infectious diseases. This is owing to the ability of plant-based vaccines to be mass produced, with higher efficiency, while maintaining lower cost compared to conventional vaccines.

For instance, in August 2018, researchers from Arizona State University’s (ASU) Biodesign Institute, developed a norovirus vaccine from tobacco plant. Genetic engineering has allowed researchers to transfer specific genes from tobacco plant in designing plant-based vaccine for norovirus. Plant-based vaccine safe and effective for use against various infectious diseases as it activates patient’s immune system.

Get PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/2004

Key players in the global plant-based vaccines market are focused on in-organic growth strategies such as strategic collaborations and acquisition to harness R&D capabilities in development of new plant-based vaccines.

For instance, in June 2016, The Texas A&M University System (including Texas A & M University AgriLife Research and the Texas A & M Institute of Infectious Animal Diseases (IIAD)), entered into agreement with iBio, Inc., and its subsidiary, iBio CMO LLC for a collaborative program in plant-produced pharmaceuticals. The collaboration is expected to leverage R&D resources of the research institute with the commercial therapeutics and vaccine development and manufacturing capabilities of iBio. The goal of the collaboration is to rapidly develop and test cost-effective, commercial, therapeutic, and vaccine solutions against various diseases such as influenza and Ebola.

Furthermore, in July 2013, Medicago, Inc., a Canada-based biopharmaceutical company, entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation, whereby Medicago was acquired by Mitsubishi with 60% share in Medicago, Inc. 40% of the shares are currently held by Philip Morris Investments B.V.

Key players operating in the global plant-based vaccines market include, Medicago, Inc., iBio, Inc., and Icon Genetics- GmbH.

Browse more detail information about: https://www.coherentmarketinsights.com/market-insight/plant-based-vaccines-market-2004

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2019 Proserve Technology, Inc.